Inside the Cross-Border Clinical Supply Chain Behind Zai Lab's DLL3 Trial

Two investigational cancer drugs, developed by two different companies in two different countries, now have to reach the same patients at the same trial sites on the same schedule. That is the operational reality behind the new Phase Ib/II study combining Boehringer Ingelheim's obrixtamig with Zai Lab's zocilurtatug pelitecan, and it says something important about how global oncology trials actually run today.

The trial targets DLL3 positive extensive stage small cell lung cancer and poorly differentiated neuroendocrine carcinomas, cancers with limited treatment options. Obrixtamig is a bispecific T-cell engager designed to direct immune cells toward DLL3 expressing tumor cells. Zocilurtatug pelitecan is an antibody-drug conjugate that delivers a cytotoxic payload directly to those same cells. Combining them means combining two separate manufacturing and supply chains as well.

Two Companies, Two Supply Chains, One Trial

Boehringer Ingelheim and Zai Lab each manufacture their own investigational drug through separate production networks. Running a combination trial means synchronizing both supply chains well enough that neither drug becomes the bottleneck for the other.

• Obrixtamig is already being evaluated across multiple global studies, including a Phase III trial, giving Boehringer Ingelheim an established production and distribution base to draw on.

• Zocilurtatug pelitecan has also advanced into its own global Phase III registrational study, meaning Zai Lab is scaling supply for more than just this combination trial alone.

• Coordinating delivery schedules across two manufacturers, each running their own separate trial programs elsewhere, adds a layer of planning complexity beyond a typical single sponsor study.

Why Biologics Make Cold Chain Logistics Non-Negotiable

Both drugs in this combination are biologics, and biologics are inherently more fragile than small molecule drugs. Temperature excursions, delays in transit or improper handling can compromise product integrity before a dose ever reaches a patient.

Global oncology trials of this scale increasingly depend on sophisticated clinical supply chain management spanning manufacturing sites in different countries. That dependence only grows as more trials combine biologics from separate sponsors rather than testing a single drug in isolation.

• Cold chain integrity has to be maintained continuously from manufacturing site to trial site, with no gaps in temperature controlled handling along the way.

• Cross-border shipments introduce customs clearance, import licensing and documentation requirements that vary by country and can each introduce delay.

• Trial sites spanning multiple countries mean local distribution networks have to be reliable enough to complete the final leg of delivery without compromising the cold chain built up over the rest of the journey.

The Underappreciated Complexity Behind the Science

Trial announcements tend to focus on mechanism of action, target biology and early efficacy signals, and understandably so. The logistics work required to actually run the trial gets far less attention, even though it directly determines whether the science can be tested at all.

This logistics complexity is often underappreciated relative to the science driving such trials, but it shapes real outcomes. A single missed shipment or customs delay at one trial site can affect enrollment timelines, dosing schedules and ultimately how quickly a trial generates usable data.

• Multi-country combination trials require redundancy planning, since a disruption at one manufacturing or distribution point cannot be allowed to stall enrollment across every site.

• Sponsors increasingly build dedicated clinical supply chain teams specifically to manage this kind of cross-border coordination rather than treating it as a downstream logistics afterthought.

• The more complex the combination, whether across companies, countries or drug modalities, the more supply chain planning has to happen well before the first patient is dosed.

What This Means for Clinical Supply and Logistics Providers

Trials like this one signal continued demand for specialized clinical trial logistics providers capable of managing multi-country, multi-sponsor biologic distribution. That is a distinct capability from standard commercial pharmaceutical distribution, given the smaller batch sizes, stricter chain of custody requirements and higher stakes tied to individual shipments.

• Providers with established cold chain networks across multiple regulatory jurisdictions are better positioned to support trials structured like this one.

• Companies running multiple global trials simultaneously, as both Boehringer Ingelheim and Zai Lab are here, benefit from logistics partners who can scale alongside expanding trial footprints.

• Combination trials pairing biologics from different sponsors may become more common as companies look for ways to improve outcomes in hard to treat cancers, which would sustain demand for this kind of specialized logistics capability.

Looking Ahead as the Trial Progresses

The Phase Ib/II study is expected to begin enrolling in 2026, with both companies drawing on established global trial infrastructure built through their respective ongoing Phase III programs. That existing infrastructure gives the combination trial a logistics head start compared with a study built entirely from scratch.

Whether that head start proves sufficient will depend on how well the two supply chains stay synchronized once enrollment ramps up across multiple countries and treatment sites simultaneously.

What Buyers and Trial Partners Should Take Away

For companies supporting clinical trial logistics, whether through packaging, distribution or cold chain services, this trial is a reminder that combination studies pairing multiple sponsors raise the operational bar significantly compared with single drug trials.